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Abstract
Background: Endometrial carcinoma is one of the most common gynecological malignancies in women. The
diagnosis of the disease at early or premalignant stages is crucial for the patient’s prognosis. To date, diagnosis and
follow-up of endometrial carcinoma and hyperplasia require invasive procedures. Therefore, there is considerable
demand for the identification of biomarkers to allow non-invasive detection of these conditions.
Methods: In this study, we performed a quantitative proteomics analysis on serum samples from simple
endometrial hyperplasia, complex endometrial hyperplasia, atypical endometrial hyperplasia, and endometrial
carcinoma patients, as well as healthy women. Serum samples were first depleted of high-abundance proteins,
labeled with isobaric tags (iTRAQ™), and then analyzed via two-dimensional liquid chromatography and tandem
mass spectrometry. Protein identification and quantitation information were acquired by comparing the mass
spectrometry data against the International Protein Index Database using ProteinPilot software. Bioinformatics
annotation of identified proteins was performed by searching against the PANTHER database.
Results: In total, 74 proteins were identified and quantified in serum samples from endometrial lesion patients and
healthy women. Using a 1.6-fold change as the benchmark, 12 proteins showed significantly altered expression
levels in at least one disease group compared with healthy women. Among them, 7 proteins were found, for the
first time, to be differentially expressed in atypical endometrial hyperplasia. These proteins are orosomucoid 1,
haptoglobin, SERPINC 1, alpha-1-antichymotrypsin, apolipoprotein A-IV, inter-alpha-trypsin inhibitor heavy chain H4,
and histidine-rich glycoprotein.
Conclusions: The differentially expressed proteins we discovered in this study may serve as biomarkers in the
diagnosis and follow-up of endometrial hyperplasia and endometrial carcinoma.
Background
Endometrial carcinoma (ECa) is one of the most com-
mon gynecological malignancies in women. During the
past two decades, the incidence of ECa in China has
been increasing consistently[ 1 ] .E n d o m e t r i o i dE C a ,t h e
predominant subtype of ECa, is preceded by a series of
precursor lesions that include simple endometrial hyper-
plasia (SEH), complex endometrial hyperplasia (CEH),
and atypical endometrial hyperplasia (AEH). To reduce
the incidence of ECa, it is preferred to diagnose and
treat patients at the stages of the various endometrial
hyperplasias before progression to ECa. Unfortunately,
examining the severity of endometrial lesions requires
invasive tissue sampling procedures [2], such as dilation
and curettage. So far, no facile and non-invasive test
exists for both the diagnosis and surveillance of endo-
metrial hyperplasia (EH) and ECa. The discovery of
changes in protein profiles that correlate with the sever-
ity of endometrial lesions and can thus be used as bio-
markers for the non-invasive diagnosis of endometrial
hyperplasia and carcinoma is thus highly desirable.
Cancer formation is accompanied by a series of pro-
tein expression change in serum and cancerous tissues
[3]. A significant number of proteomics studies have
been reported in which tissue and/or blood samples
from ECa patients have been analyzed [4-17]. However,
most of these studies only compared samples between
cancer patients and healthy women, and thus lacked the
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provided by directly analyzing endometrial hyperplasia
samples. The only proteomics investigation that has
focused on endometrial hyperplasia identified several
proteins with altered expression exclusively in resected
endometrial hyperplasia tissue [12]. However, biomarker
candidates discovered from tissue samples need to be
further evaluated in body fluids (e.g. blood and urine)
that can be used more practically for diagnosis.
Clinical biomarker discovery using proteomic
approaches has been limited by a relatively high varia-
tion in sample preparation techniques and by the low
reproducibility of quantitative measurement using mass
spectrometry (MS). The development of isobaric tags
for relative and absolute quantification (iTRAQ), which
allows simultaneous measurement of multiple (up to 8)
samples in one experimental run, significantly reduces
the potential variation in multiple MS runs, and thus
improves the accuracy of protein identification and
quantification [18]. The iTRAQ technology has been
successfully applied to biomarker discovery for many
conditions in both tissue [4] and serum samples [19].
In this study, we reported a quantitative proteomics
analysis using the iTRAQ technology to investigate pro-
tein changes in serum during the multiple stages of dis-
ease progression in ECa. With the iTRAQ technology,
we specifically compared serum samples from multiple
stages of hyperplasias (SEH, CEH, and AEH) and ECa.
We found several proteins with altered expression levels
during disease progression that could represent serum
biomarker candidates in EH and ECa.
Results and discussion
In this study, iTRAQ technology in combination with
2D LC-MS/MS was applied to detect differentially
expressed proteins in EH and ECa. Serum samples from
20 patients (6 patients of SEH, 4 of CEH, 4 of AEH, and
6 of stage I endometrioid ECa) and 7 healthy women
who were free of metabolic disorders were used.
Although expression of serum high-abundance proteins
were reported to show stage correlative changes in some
malignant conditions [20], we applied a serum depletion
procedure (see Materials and Methods for details) in
this study to deplete the high-abundance proteins that
could interfere with the detection of low-abundance
proteins of greater biological interest. Proteins from
depleted serum samples were digested into peptides,
individually labeled with iTRAQ reagents, combined,
and subjected to LC-MS/MS analysis.
This iTRAQ-based proteomics analysis led to the
identification of a total of 15209 peptides, 3766 of which
were unique. These identified peptides correspond to a
set of 430 proteins with more than 95% confidence
(ProtScore > = 1.3). Among them, 74 non-redundant
proteins were successfully quantified with average ratios
presented. The iTRAQ ratios were calculated over the
control samples from normal individuals (iTRAQ chan-
nel 117). Because we applied the depletion procedure to
remove the high-abundanc proteins, these proteins were
not included in further data analyses.
An overview of the resulting set of proteins is shown
in Figure 1. The majority of proteins do not appear to
be ECa-related because their expression levels show no
linear correlation with the disease progression (Figure
1A). Gene Ontology analysis indicated that these pro-
teins are primarily constitutional serum proteins
involved in typical blood pathways including transport,
immune response, or blood coagulation (Figure 1B-1E).
However, we did identify several proteins whose expres-
sion levels were significantly increased or decreased
among the stages of EH and ECa (Figure 2)
Using a 1.6-fold quantification cutoff for those proteins
with a relatively significant change, 12 proteins quantified
at least once in the four disease groups show significant
changes in their expression and were followed as poten-
tial cancer markers (Figure 2 and Table 1). Four of these
proteins, including serum amyloid A (SAA), apolipopro-
tein A-IV (ApoA4), antithrombin III (synonymous with
SERPINC1), and inter-alpha-trypsin inhibitor heavy chain
H4 (ITIH4; synonymous with inter-alpha-trypsin inhibitor
family heavy chain-related protein, IHRP), have been
reported previously (Table 2). Our detection of SAA,
ApoA4, and antithrombin III is consistent with previous
reports, while the opposite result has been observed for
ITIH4 [6,16,21].
ITIH4 protein is a 120KD glycoprotein, which is prone
to be cleaved to produce fragments of different length
[16]. In the previous studies, serum level of ITIH4 in
ECa patients was reported to be upregulated [6]. After
MS analysis, these ITIH4 were identified as 35KD frag-
ment of the whole ITIH4 protein [16,21]. In this study,
iTRAQ method is unable to differentiate cleaved frag-
ments from whole protein. All fragments encoded by
ITIH4 gene were used for ITIH4 quantitation. This may
be the basis of the contradictory result and low confi-
dence of quantitation (p = 0.09) in this study.
Two proteins, serum amyloid A protein precursor and
serum amyloid A2 isoform a, showed significant eleva-
tion in ECa as compared with the normal control. Inter-
mediate upregulation of these two proteins was also
observed in the serum samples from AEH, CEH, and
SEH (Figure 2). SAA proteins belong to a family of apo-
lipoproteins that are synthesized mainly in the liver in
response to inflammatory stimuli as acute-phase pro-
teins [22]. The expression levels of these proteins in
serum have been found to increase in a broad spectrum
of neoplastic diseases, and high levels have been posi-
tively correlated with metastasis and poor prognosis
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Page 2 of 8[23]. A study in colon carcinoma has demonstrated gra-
dually increased expression of SAA as epithelial cells
progress from dysplasia to neoplasia, suggesting that this
protein plays a role in colonic tumorigenesis [24]. Pre-
vious proteomic analyses of ECa tissues did not
observed significantly altered expression of SAA in can-
cerous tissue [4,7,8,10,25]. However, downregulation of
the SAA2 gene has been observed in one study using
micro-dissected endometrioid endometrial carcinoma
tissues [26]. Thus, it remains to be determined whether
the elevation of SAA levels in the serum of ECa patients
originates from liver secretion or from endometrial can-
cerous tissues.
Three additional proteins, apolipoprotein C-II precur-
sor, apolipoprotein E precursor, and apolipoprotein A-
IV precursor, showed consistently altered expression
with high confidence levels in the four disease groups
(Figure 2). Upregulation of apolipoprotein C-II precur-
sor and apolipoprotein E precursor in SEH and downre-
gulation of apolipoprotein A-IV precursor in CEH and
AEH were of significance according to the given
benchmark. Patients with EH and ECa also usually have
the complication of a lipid metabolism disorder. In the
present study, all participants were free of hyperlipoide-
mia at enrollment, and serum samples were collected
after a fasting period of more than 8 hours. However,
abnormal apolipoprotein levels still presented. This
result may imply a systemic impairment of lipid metabo-
lism in EH and ECa patients.
Histidine-rich glycoprotein (HRG) precursor was
downregulated in the four disease groups, with a ratio
over the benchmark only in atypical hyperplasia (Figure
2). HRG is a member of the cystatin superfamily. A
study of HRG-knockout mice has suggested a property
of mild anti-coagulant and anti-fibrinolytic activity of
HGR in vivo [27]. Other properties of HRG, such as
antibacterial activity [28], have also been reported. HRG
was found to exert anti-tumor effects in vivo through
the inhibition of tumor vascularization [29]. Although
downregulation of HRG reached the benchmark only in
atypical hyperplasia in the present study, this result may
suggest a propensity for patients to progress to ECa.
Figure 1 Overview of protein identification and quantitation results. (A) Average ratio of proteins in SEH, CEH, AEH, and ECa groups. (B)
PANTHER analysis for molecular function, (C) protein class, (D) biological process, and (E) pathway of identified proteins.
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Page 3 of 8Table 1 List of proteins identified as potential cancer markers in the serum of endometrial hyperplasia and carcinoma
patients
N %Cov Accession Protein Name (Gene Symbol)
1 42.19 IPI00550991 alpha-1-antichymotrypsin precursor (SERPINA3)
2 55.98 IPI00844156 antithrombin III(SERPINC1)
3 90.40 IPI00304273 apolipoprotein A-IV precursor (APOA4)
4 94.06 IPI00021856 apolipoprotein C-II precursor (APOC2)
5 64.98 IPI00021842 apolipoprotein E precursor (APOE)
6 68.57 IPI00641737 haptoglobin precursor (HP)
7 71.05 IPI00022371 histidine-rich glycoprotein precursor (HRG)
8 25.58 IPI00305380 insulin-like growth factor-binding protein 4 precursor (IGFBP4)
9 57.78 IPI00218192 inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4)
10 42.29 IPI00884926 orosomucoid 1 precursor (ORM1)
11 99.18 IPI00552578 serum amyloid A protein precursor (SAA1;SAA2)
12 100.00 IPI00006146 serum amyloid A2 isoform a (SAA1;SAA2)
Figure 2 Expression profiles of 12 proteins with significant changes in endometrial hyperplasia or carcinoma. (*), Expression change
greater than 1.6-fold, i.e. average ratio >1.6 or <0.625, when compared with normal control.
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a n dE C a ,b u td o w n r e g u l a t e di nC E Ha n dS E Hw i t hh i g h
confidence (Figure 2). An elevated serum concentration
of this protein has been associated with several malignant
diseases, such as lung cancer [30] and cervical cancer
[31]. One recent report on HP expression levels in
endometrioid adenocarcinoma tissue has reported a gen-
eral upregulation of mRNA and protein levels of HP in
both cancerous and adjacent non-affected endometrial
tissues [32]. These data suggest that endometrial tissue
can be one of the origins, though not the only one,
responsible for elevated serum HP levels in ECa patients.
Table 2 Potential cancer markers for endometrial hyperplasia and carcinoma reported in previous literatures
Protein Name Endometrial Carcinoma Endometrial Hyperplasia
Tissue Serum/Plasma Tissue Serum/Plasma
alpha-1-antitrypsin -[6]
alpha-1-antitrypsin precursor -[4]
alpha-1-beta glycoprotein +[6]
alpha-enolase +[12]
antithrombin III +[6]*
apolipoprotein A-IV -[16]*
calcyphosine +[14]
calgizzarin +[4]
calgranulin A +[11]
cAMP dependent protein kinase type I-beta regulatory chain +[12]
chaperonin 10 +[4,7,11]
cleaved high molecular weight kininogen -[4,6]
clusterin +[6]
complement component 3 +[16]
complement component 4A +[16]
complement component 4B +[16]
creatine kinase B -[4]
cyclophilin A +[14,17]
epidermal fatty acid binding protein +[14]
GAPDH +[12]
heat shock 27 kDa protein +[12]
heat shock 70 kDa protein 1 +[12] +[12]
heat shock cognate 71 kDa protein +[12] +[12]
heterogeneous nuclear ribonucleoprotein D0 +[4]
heterogeneous nuclear ribonucleoproteins A2/B1 +[12]
inter-alpha-trypsin inhibitor family heavy chain-related protein (IHRP) +[6,16,21]
#
leucine-rich glycoprotein +[6]
macrophage migratory inhibitory factor +[4]
phosphoglycerate kinase +[12] +[12]
polymeric immunoglobulin receptor precursor +[4]
prohibitin +[12]
prolactin +[15]
pyruvate kinase M1 or M2 isozyme +[4]
serotransferrin precursor +[12]
serum albumin precursor +[12] +[12]
serum amyloid A +[15]*
transgelin -[4]
trypomyosin fibroblast isoform TM3 +[12]
vimentin +[12]
References are indicated in brackets;
“+”, up-regulation;
“-”, down-regulation;
“*”, consistent result in this study when compared with previous studies;
“#”, contradictory result in this study when compared with previous studies.
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(IGFBP-4) was upregulated significantly in SEH and to a
mild extent in CEH and ECa (Figure 2). The relation-
ship between the serum level of IGFBP and ECa risk
remains controversial [33,34]. The relationship between
the expression of IGFBP-1, IGFBP-2, and IGFBP-3 with
endometrial carcinoma has been frequently investigated.
Little is known about IGFBP4.
Conclusions
In conclusion, we conducted a serum proteomic analysis
of endometrial hyperplasia and carcinoma using iTRAQ
technology and 2D LC-MS/MS. In addition to the upre-
gulation of SAA in ECa, we report for the first time the
altered expression level of 7 proteins in AEH. These
proteins may serve as potential biomarkers for the early
diagnosis and surveillance of endometrial carcinoma and
hyperplasia.
Methods
Samples
This study was approved by the institutional review
boards of the Obstetrics and Gynecology Hospital,
Fudan University, Shanghai, P.R. China. All participants
provided written informed consent at enrollment. For
proteomic analysis, untreated, pathologically confirmed
EH and stage I endometrioid ECa patients were enrolled
in this study from May 2007 to February 2009. Healthy
women undergoing routine physical examinations were
recruited as normal controls (NC) during the same per-
iod. Because metabolic disorders, such as hypertension,
diabetes mellitus, and hyperlipoidemia, result in obvious
changes in protein expression in serum [35], all partici-
pants with these disorders were excluded from this
study. Ultimately, 20 patients with endometrial lesions
(including 6 SEH, 4 CEH, 4 AEH, and 6 stage I endo-
metrioid ECa) and 7 healthy women were enrolled. The
median ages at diagnosis were 46 years (range 43 to 52),
40 years (range 28 to 46), 33 years (range 29 to 40), and
53 years (range 44 to 62) for SEH, CEH AEH, and ECa
patients, respectively. The median age of NCs was 46
years (range 45 to 47). Four women in the ECa group, 1
in the SEH group, none in the CEH group, and 1 in the
NC group were postmenopausal. Five milliliters of blood
samples were taken from each participant. After clotting
and centrifuging at 2000 rpm for 10 min, the serum was
stored at -80°C until use.
Depletion of high-abundance proteins
Serum samples were thawed on ice. Equal amounts of
serum from individuals in each group were pooled to
yield 5 distinct pools of 600 μl each. High-abundance
proteins of each serum pool were depleted using Proteo-
Miner Protein Enrichment Kits (Bio-Rad, USA)
according to the manufacture’s instruction. Briefly,
serum was loaded onto the column and proteins bound
with high specificity to a bead-based library of diverse
peptide ligands. High-abundance proteins which satu-
rated their corresponding ligands were washed out of
the column. The remaining low- and mid-abundance
proteins in the column were then eluted and collected.
The eluents were precipitated using a Ready Prep 2-D
Cleanup Kit (Bio-Rad, USA). The total protein concen-
trations were determined by a Bradford protein assay as
previously described [36].
iTRAQ reagent labelling
After high-abundance protein depletion and concentra-
tion measurements, aliquots of 100 μgp r o t e i nf r o m
each of the 5 sample pools were reduced, blocked on
cysteines, and digested overnight at 37°C with trypsin,
as described in the iTRAQ protocol. Peptides were then
labeled individually with one iTRAQ tag (Applied Bio-
systems, USA) as follows: ECa, 113.1; SEH, 114.1; CEH,
115.1; AEH, 116.1; NC, 117.1. The labeled peptides were
then pooled and dried using a rotary vacuum concentra-
tor (Christ RVC 2-25, Christ, Germany).
Strong cation exchange chromatography (SCX)
Strong cation exchange chromatography was performed
on the ACQUITY Ultra Performance LC system
(Waters, USA). Tryptic-digested and labeled peptides
were loaded onto a 0.5 × 23 mm, 5 μm, 300 Å Column
(Waters, USA) and eluted stepwise by injecting salt
plugs of 10 different molar concentrations of 25, 50, 75,
100, 150, 200, 300, 400, 500, and 1000 mM NH4AC.
Ten fractions were collected from the SCX column.
LC-MS/MS
Fractions from the SCX column were analyzed on a Qstar
XL LC/MS/MS system (Applied Biosystems, USA). Each
fraction was loaded onto a ZORBAX 300SB-C18 reverse
phase (RP) column (5 μm, 300 Å, 4.6 × 50 mm, Agilent,
USA). Buffer A was composed of 5% acetonitrile, 95%
water, and 0.1% formic acid, and Buffer B was composed
of 95% acetonitrile, 5% water, and 0.1% formic acid. The
elution was performed using a gradient ranging from 5%
to 45% Buffer B at a flow rate of 0.4 μl/min for 90 min.
The LC eluent was directed to a nano-flow electrospray
source for MS/MS analysis in an information dependent
acquisition mode. A TOF MS survey scan was acquired
from 400-1800 m/z, with up to the 6 most intense multi-
ply charged ions in the survey scan sequentially selected
for MS/MS analysis. Product ion spectra were accumu-
lated for 2 s in the mass range 100-2000 m/z with a modi-
fied Enhance All mode Q2 transition setting favoring low
mass ions, so the reporting iTRAQ ion (113.1, 114.1,
115.1, 116.1, and 117.1 m/z) intensities were enhanced for
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analyzed in duplicate.
Protein identification and relative quantitation
MS/MS data was searched against the International Pro-
tein Index (IPI) database (version 3.45, HUMAN) using
ProteinPilot™ software (version 2.0, Applied Biosystems,
USA) with trypsin set as the digestion enzyme and
methyl methanethiosulfonate as the cysteine modifica-
tion. The search results were further processed by Pro-
teinPilot™ software using the ProGroup Algorithm for
redundant hits removing and comparative quantitation,
resulting in the minimal set of justifiable identified pro-
teins. Proteins with more than 95% confidence (Prot-
Score > = 1.3) were reported. Relative quantitation of
peptides was calculated as a ratio by dividing the
iTRAQ reporter intensity at 113.1, 114.1, 115.1, and
116.1 m/z by that at 117.1 m/z. The quantitation results
were normalized for loading error among the 5 groups
by bias correction calculated automatically by the Pro-
teinPilot™ software. The ratios of peptides that support
the existence of one protein were averaged for protein
relative quantitation. A p-value was reported after one
sample t-test of averaged protein ratio against 1 to
assess the validity of the protein expression change. Pro-
tein ratios with a p-value less than 0.05 were considered
reliable. Standard deviations (SD) of the protein ratio,
which stem from technical variation, were reported to
be less than 0.3 in 90% of iTRAQ experimental runs
[37]. Therefore, we used a difference of 2 SDs, ie.p r o -
tein ratio greater than 1.6 or smaller than 0.625, as an
approximate benchmark for variation in protein expres-
sion. Expression changes greater than 1.6-fold in nor-
malized expression levels were considered to be outside
the range of technical variability.
PANTHER analysis
The molecular function, protein classification, biological
process and signaling pathway of proteins identified in
this study were elucidated by searching against the
PANTHER database. (http://www.pantherdb.org).
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